JPET #57752 5 contributing to the resistance of the gastric mucosa against damaging agents. This concept was strengthened by studies demonstrating that selective COX-2 inhibitors are not ulcerogenic in experimental animals (Masferrer et al., 1994) and cause less gastrointestinal side effects than standard non-steroidal anti-inflammatory drugs in humans (Hawkey, 1999) .
Recently, however, it was shown that in normal rats neither selective inhibition of COX-1 nor of COX-2 injures the gastric mucosa. Gastric lesions only developed when both COX isoenzymes were simultaneously inhibited (Wallace et al., 2000; Gretzer et al., 2001; Tanaka et al., 2001) implicating a role for COX-2 in gastric mucosal defense. This view is supported by observations that COX-2 represents a protective factor involved in gastric mucosal resistance in the face of pending injury. Thus, in the rat stomach, COX-2 inhibitors abolished the protection induced by the mild irritant 20% ethanol against a subsequent challenge with 70% ethanol , partially antagonized the protection caused by intragastric perfusion with peptone against ethanolinduced injury and markedly aggravated gastric damage induced by ischemiareperfusion (Maricic et al., 1999) . Furthermore, non-selective COX inhibitors and selective COX-2 inhibitors delayed the healing of chronic gastric ulcers in mice (Mizuno et al., 1997) and rats (Schmassmann et al., 1998) to the same extent.
The present study investigates whether the interaction of prostaglandins with NO and afferent neurons in the modulation of gastric mucosal integrity involves COX-1 and/or COX-2. To answer this question, we evaluated the effects of the selective COX-1 inhibitor [5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole] (SC-560) (Smith et al., 1998) , the selective COX-2 inhibitors N-[2-(cyclohexyloxy)-4-nitrofenyl]-methanesulphonamide (NS-398) (Futaki et al., 1994) , and 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5II)-furanone (DFU) (Riendeau et al., 1997) as well as the glucocorticoid dexamethasone which inhibits the upregulation of gastric COX-2 (Gretzer et al., 2001 ) on gastric mucosal integrity. The studies were performed in rats treated with the non-selective inhibitor of constitutive and inducible NO synthase N G -monomethyl-L-arginine methyl ester (L-NAME) (Rees et al., 1990) , or the selective inhibitor of from Qbiogene-Alexis, Grünberg, Germany, capsaicin from Fluka, Neu-Ulm, Germany. All other chemicals were purchased from Sigma Chemicals Co. (St. Louis, MO, U.S.A.).
Animals.
Male Wistar rats (180-220 g) were fasted overnight with free access to tap water. The studies reported in this article have been carried out in accordance with the Guide for the Care and
Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health.
All experimental protocols were approved by the Animal Care Committee of the Ruhr-University of Bochum.
Gastric Mucosal Damage. Rats were anaesthetized (pentobarbital, 50 mg/kg, i.p.), tracheotomized and the stomachs exposed by a mid-line incision. After ligation of the esophagus and pylorus, 1 ml of HCl (300 mM) was injected into the gastric lumen through the forestomach.
Forty-five min later, the stomach was excised and gastric mucosal damage assessed. Further rats were treated intragastrically with 1 ml of water instead of acid. In sham operated rats, the abdomen was opened in anesthesia and the esophagus and pylorus manipulated without ligations.
Gross mucosal damage was assessed in a blinded manner by calculation of a lesion index using a 0-3 scoring system based on the number and length of the lesions as described previously (Stroff et al., 1996) . The severity factor was defined according to the length of the lesions: 0, no lesions visible; I, lesions < 1 mm; II, lesions 2 to 4 mm; and III, lesions > 4 mm. The lesion index was calculated as the total number of lesions multiplied by their respective severity factor. Normal rats do not show gastric lesions (lesion index 0), a lesion index below 10 represents minor damage, a lesion index above 30 severe damage.
For histological study, a strip of the stomach wall parallel to the limiting ridge was processed using routine methods, stained with H&E and examined under a light microscope in a randomized This article has not been copyedited and formatted. The final version may differ from this version. were assessed: grade 1, superficial damage confined to the surface epithelium; grade 2, deep damage extending beyond the surface epithelium into the region of pits and glands as described before For each stomach strip the length of mucosal areas showing superficial and deep damage was determined and expressed as % of the total section length, which is the full length portion of tissue across the entire corpus, studied.
Treatment Regimens. Groups of rats were treated with the selective COX-2 inhibitors DFU (0.02-2 mg/kg, s.c.) or NS-398 (0.01-1 mg/kg, s.c.), the selective COX-1 inhibitor SC-560
(0.05-5 mg/kg, s.c.), phenacetin (400 mg/kg, s.c.) 60 min, or dexamethasone (1 mg/kg, s.c.)
120 min before intragastric instillation of 1 ml of 300 mM HCl. These rats received concurrent treatment with the non-selective inhibitor of constitutive and inducible NO synthase L-NAME (40 mg/kg, i.v.) 10 min before acid challenge. Phenacetin was used as it was reported to inhibit COX-3 more potently than its metabolite acetaminophen (Chandrasekharan et al., 2002 Capsaicin-pretreated rats received s.c. DFU (0.02-2 mg/kg), NS-398 (0.01-1 mg/kg), dexamethasone (1 mg/kg), or SC-560 (5 and 10 mg/kg) following the time schedule outlined above.
These rats did not receive concurrent treatment with L-NAME. No differences in mucosal integrity were observed in capsaicin-pretreated rats that received either intragastric instillation of HCl alone or treatment with the various vehicles before acid instillation.
Effect of Prostaglandin Supplementation.
To examine whether the effects of COX inhibitors and dexamethasone are related to suppression of endogenous prostaglandins, rats with intact or denervated afferent neurons received concurrent treatment with 16,16-dimethyl-PGE 2 (dissolved in 70% ethanol). The prostaglandin analog (8 ng/kg) was injected s.c. 5 min before treatment with DFU, NS-398, dexamethasone, or SC-560 and immediately before intragastric acid instillation. Rats with intact afferent neurons were treated additionally with i.v. injections of L-NAME 10 min before acid instillation. In these experiments the dose of L-NAME was reduced to 3 mg/kg as pilot experiments had shown that the damage-inducing effects of COX inhibitors and dexamethasone could not be reversed by the prostaglandin analog in rats treated simultaneously with L-NAME at the high dose of 40 mg/kg. Capsaicin-pretreated rats did not receive additional injections of L-NAME. A flow sheet of the experimental procedures used is shown in Fig. 1 .
To ascertain that 16,16-dimethyl-PGE 2 at the dose used has no general gastroprotective activity, the prostaglandin analog (8 ng/kg) was injected s.c. 65 min and immediately before intragastric challenge with 70% ethanol and mucosal damage was assessed 5 min later. (3.0 mg/kg) had no effect (lesion index 3±0.7, n=4). However, in acid-challenged rats treated with L-NAME (40 mg/kg, i.v), concurrent administration of DFU (0.02-2 mg/kg, s.c.) or NS-398 (0.01-1 mg/kg, s.c.) caused marked and dose-related damage to the gastric mucosa ( Fig. 2, 
Results

Effect of Suppression of COX Isoenzymes in Rats with
panel B).
Likewise, dexamethasone (1 mg/kg, s.c.) induced severe mucosal injury in L-NAME-treated rats whereas phenacetin (400 mg/kg, s.c.) was without effect (Fig. 2, panel B) . In rats treated with the inactive enantiomer D-NAME (3 or 40 mg/kg, i.v), DFU (2 mg/kg, s.c.) induced no or significantly less gastric injury compared with rats treated with the corresponding dose of L-NAME. Likewise, D-NAME (3 mg/kg) did not provoke damage following administration of NS-398 (1 mg/kg) ( Fig. 3) . Furthermore, administration of DFU (2 mg/kg, s.c.) or NS-398 (1 mg/kg, s.c.) caused only slight and no mucosal damage, respectively, in rats treated with the selective inhibitor of inducible NO synthetase 1400W (Fig. 3) . In contrast to COX-2 inhibitors and dexamethasone, SC-560 (0.05-5 mg/kg, s.c.) moderately damaged the acid-challenged mucosa in a dose-dependent manner even without concurrent treatment with L-NAME. This damage was significantly aggravated after simultaneous administration of L-NAME (40 mg/kg, i.v.) (Fig. 4) . Likewise, in capsaicin-pretreated rats, 16,16-dimethyl-PGE 2 (8 ng/kg, s.c., same time schedule as described above) prevented the development of mucosal damage induced by DFU (2 mg/kg, s.c.), NS-398 (1 mg/kg, s.c.), dexamethasone (1 mg/kg, s.c.), or SC-560 (10 mg/kg, s.c.) (Fig. 7) .
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Histological Injury. Sham operated rats did not show any histological injury of the gastric mucosa (results not shown). Fig. 8 shows the occurrence of superficial and deep histological injury (expressed as % of section length studied) in the various treatment groups. In rats with intact afferent neurons, histological injury was negligible after acid instillation alone. Furthermore, histological injury was negligible or absent in acid-challenged rats after administration of L-NAME (40 mg/kg, i.v.) (Fig. 8) , DFU (2 mg/kg, s.c.), or dexamethasone (1 mg/kg, s.c.) alone whereas SC-560 (5 mg/kg, s.c.) induced moderate injury (data not shown). Severe histological injury was observed in L-NAME-treated rats after concurrent administration of DFU (2 mg/kg), dexamethasone (1 mg/kg), or SC-560 (5 mg/kg, s.c.) (Fig 8) . In capsaicin-pretreated rats, acid instillation alone did not induce histological injury. Such damage was, however, apparent in acidThis article has not been copyedited and formatted. The final version may differ from this version. (1 mg/kg, s.c.), or SC-560 (5 mg/kg, s.c.) in denervated rats (Fig. 8) .
The effects of inhibition of afferent nerve function, NO, COX-1, or COX-2 alone or in combination on gastric mucosal integrity are summarized in Table 1 .
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
High levels of COX-1 mRNA occur in the gastric mucosa of normal (Kargman et al., 1996; Ferraz et al., 1997) or sham operated rats and after intragastric instillation of saline whereas levels of COX-2 mRNA are low (Gretzer et al., 2001) . Instillation of acid (300 mM HCl) resulted in upregulation of mucosal COX-2 mRNA without change in the expression of COX-1 (Gretzer et al., 2001 ). Acid-induced expression of COX-2 mRNA in the rat stomach was also reported by Sawaoka et al. (1997) . These authors, however, used a higher concentration of acid (600 mM HCl) that caused severe macroscopic mucosal injury and widespread histological changes. Sawaoka et al. (1997) concluded that the up-regulation of gastric COX-2 is the consequence of the injury following instillation of concentrated acid. In our experiments using a lower concentration of acid, no macroscopic and histological damage was found indicating that acid can induce COX-2 expression in the absence of mucosal damage (Gretzer et al., 2001) . Our experiments also showed that dexamethasone prevents the gastric up-regulation of COX-2 associated with acid instillation whereas levels of COX-1 mRNA were not affected.
The present study confirms that in rats with intact afferent neurons the macroscopic and histological appearance of the gastric mucosa after instillation of 300 mM HCl is comparable to that in sham operated rats or rats treated with intragastric water. After administration of L-NAME, DFU, NS-398, or dexamethasone alone, mucosal damage remained negligible. However, when L-NAMEtreated rats received concurrent treatment with the COX-2 inhibitors DFU or NS-398 or dexamethasone before acid instillation, severe and dose-related mucosal injury developed. The specific nature of this action of L-NAME was demonstrated by the finding that DFU and NS-398 induced significantly less gastric damage in rats treated with the inactive enantiomer D-NAME compared with L-NAME-treated rats.
NO involved in the regulation of gastric mucosal integrity under the experimental conditions employed in the current study is generated predominantly via the constitutive NO synthase pathway. This is suggested from the finding that the ulcerogenic potency of DFU and NS-398 after treatment with 1400W, a highly selective inhibitor of inducible NO synthase (Garvey et al., 1997) , is significantly lower or absent compared with that after treatment with L-NAME, a dual inhibitor of constitutive and inducible NO synthase (Rees et al., 1990) . Increasing the dose of 1400W to 1 mg/kg or prolonging the period between administration of COX-2 inhibitors and injection of 1400W to 80 min did not increase the ulcerogenic activity of the COX-2 inhibitors (data not shown). The dose of 1400W (0.3 mg/kg) used in the present study was previously shown to abolish the lack of ulcerogenicity of the non-steroidal anti-inflammatory drug amtolmetin guacyl in the rat stomach (Peskar et al., 2002) . The low gastrotoxicity of amtolmetin guacyl has been attributed to up-regulation of the inducible NO synthase (Coruzzi et al., 2002) .
In normal rats, selective inhibition of COX-1 or COX-2 did not injure the gastric mucosa and damage only developed after simultaneous suppression of both isoenzymes (Wallace et al., 2000; Gretzer et al., 2001; Tanaka et al., 2001) . Whereas after intragastric instillation of acid COX-2 inhibitors were still devoid of ulcerogenic properties, mucosal damage occurred after administration of SC-560 (Gretzer et al., 2001) . Obviously, in the normal stomach, mucosal integrity is preserved when either COX-1 or COX-2 is functioning. In contrast, in the face of pending injury, COX-2 alone is not sufficient to ensure the maintenance of mucosal viability. This observation was confirmed in the present study where SC-560 caused dose-dependent mucosal injury in the acidchallenged stomach even without suppression of NO synthase. SC-560-induced damage was, however, significantly aggravated after co-treatment with L-NAME. Taken together, these findings show that the endogenous NO system limits or even prevents the damaging effects of inhibitors of both COX-1 and COX-2. This is in line with observations that NO-releasing non-steroidal antiinflammatory drugs cause markedly reduced damage to the gastric mucosa (Wallace et al., 1994) .
Recently, a third COX isoenzyme, COX-3, was described in canine and human cerebral cortex and human heart (Chandrasekharan et al., 2002) . Whether this splice variant of COX-1 also occurs in gastric tissues has not been investigated. Chandrasekharan et al. (2002) found that various nonThis article has not been copyedited and formatted. The final version may differ from this version. steroidal anti-inflammatory drugs block the activity of COX-3 with phenacetin being the most selective inhibitor. Treatment of rats with phenacetin (400 mg/kg, s.c.) did not damage the gastric mucosa in L-NAME-treated and acid-challenged rats. Increasing the dose of phenacetin to 800 mg/kg had not more effect (data not shown). Phenacetin administered i.p. at 400 mg/kg significantly reduced the intensity of hyperalgesia assessed in a modified Randall-Selitto test indicating in vivo activity of the drug at this dose (Ferreira et al., 1978) . The lack of effect of phenacetin in our experiments does not support a role for COX-3 in gastric mucosal resistance, although further studies are needed to elucidate a possible contribution of this COX isoform in various gastric functions.
In rats treated with capsaicin to deplete neuropeptides, the presence of intragastric acid did not induce any macroscopic or histological damage. After afferent nerve denervation, administration of DFU, NS-398, dexamethasone, or SC-560 caused severe gastric lesions even without concurrent treatment with L-NAME. Dose-dependency of the injurious effects was demonstrated for the COX-1 inhibitor and the COX-2 inhibitors.
Neuropeptide-containing afferent neurons are present in abundance in the gastric mucosa (Sternini et al., 1987) . Activation of afferent neurons by a low dose of capsaicin exerts protection against a variety of ulcerogens (Holzer, 1998) . This protection is mainly mediated by release of the neuropeptide calcitonin gene-related peptide (CGRP) (Lambrecht et al., 1993) . The protective effects of both afferent nerve stimulation and CGRP are abolished by pretreatment with L-NAME.
From these findings we have proposed that afferent nerve stimulation promotes the release of CGRP which activates formation of NO. NO then represents the final mediator of protection (Lambrecht et al., 1993) . High activity of constitutive NO synthase has been measured in rat gastric mucous-epithelial cells (Brown et al., 1992) . Vascular endothelial cells (Moncada et al., 1991) and gastrointestinal smooth muscle cells (Grider et al., 1992) myenteric plexus of the gastrointestinal tract (Bredt et al., 1990) . Furthermore, NO is released upon electrical stimulation of nonadrenergic noncholinergic nerves in the rat stomach fundus (Boeckxstaens et al., 1991) . Whether neuronally derived NO contributes to protective effects has not been established. The sequence outlined above can explain why both depletion of neuropeptides and blockade of NO synthase interfere with the maintenance of gastric mucosal integrity when prostaglandin formation is reduced.
SC-560 potently inhibited formation of gastric 6-keto-PGF 1α and PGE 2 and platelet thromboxane (TX) B 2 as expected for a COX-1 inhibitor (Gretzer et al., 2001 ). The COX-2 inhibitors DFU and NS-398 at doses comparable to those used in the present study did not inhibit platelet TXB 2 formation Maricic et al., 1999; Gretzer et al., 2001) indicating that the effects observed with these compounds are not accounted for by lack of selectivity. We and others Maricic et al., 1999; Wallace et al., 2000; Gretzer et al., 2001) could not demonstrate that in rats COX-2 inhibitors reduce prostaglandin formation in non-ulcerated gastric mucosa. This phenomenon may be due to the fact that COX-2-derived prostaglandins represent only a small portion of the total gastric mucosal prostaglandin pool which renders isolated assessment of changes of COX-2 activity difficult. NS-398 and DFU, however, reduced PGE 2 levels in rat inflammatory tissue indicating potent COX-2 inhibitory activity Gretzer et al., 2001 ). The proposal that the effects of DFU and NS-398 observed in L-NAME-treated and denervated rats are due to suppression of prostaglandin formation is supported by the finding that 
